<p>IGM Biosciences（纳斯达克代码：IGMS - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的股票研究人员上调至 “持有” 评级。</p>
<p>获取 <strong>IGM Biosciences</strong> 的提醒：</p>
<h2>IGM Biosciences 价格表现</h2>
<p>IGMS 股票在周五开盘价为 $1.27。该股票的 50 日简单移动平均线为 $1.27，200 日简单移动平均线为 $1.28。IGM Biosciences 的 52 周低点为 $0.92，52 周高点为 $22.50。该股票的市值为 7657 万美元，市盈率为 -1.41，贝塔值为 0.60。</p>
<p>IGM Biosciences（纳斯达克代码：IGMS - 获取免费报告）最近在 7 月 31 日（星期四）公布了其财报。公司报告本季度每股收益为 $1.58，超出市场普遍预期的 ($0.30) 1.88 美元。IGM Biosciences 的股本回报率为 -93.35%，净利润率为 -36.81%。该公司在本季度的收入为 1.4362 亿美元，而分析师的预期为 320 万美元。平均而言，卖方分析师预计 IGM Biosciences 本年度每股收益为 -3.35。</p>
<h2>机构投资者对 IGM Biosciences 的看法</h2>
<p>几家对冲基金最近调整了对 IGMS 的持仓。XTX Topco Ltd 在第二季度以 30,000 美元的估值新建了对 IGM Biosciences 的持仓。Invesco Ltd. 在第一季度以 42,000 美元的估值新建了对 IGM Biosciences 的持仓。Marshall Wace LLP 在第二季度以 50,000 美元的估值新建了对 IGM Biosciences 的持仓。Nuveen LLC 在第一季度以 52,000 美元的估值新建了对 IGM Biosciences 的持仓。最后，德意志银行在第一季度将其在 IGM Biosciences 的持仓增加了 316.6%。德意志银行目前拥有 46,773 股该公司的股票，估值为 54,000 美元，此前在此期间又购买了 35,546 股。42.79% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>IGM Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>IGM Biosciences, Inc. 是一家临床阶段的生物技术公司，开发用于治疗癌症以及自身免疫和炎症性疾病的免疫球蛋白 M（IgM）抗体。它开发了 Aplitabart，一种用于治疗结直肠癌的死亡受体 5 激动剂 IgM 抗体；imvotamab，一种 CD20 x CD3 双特异性 IgM 抗体，用于治疗肌炎，以及用于治疗系统性红斑狼疮和类风湿关节炎，目前处于 I 期临床试验阶段；以及 IGM-2644，一种双特异性 T 细胞结合 IgM 抗体，靶向 CD38 和 CD3 蛋白，用于治疗自身免疫疾病。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 IGM Biosciences</li>
<li>如何在衰退中持有这些分红之王</li>
<li>3 只餐饮股票将在第三季度和第四季度表现优于大盘</li>
<li>如何交易便士股票：逐步指南</li>
<li>持续上涨的中游能源投资</li>
<li>便士股票适合你的投资组合吗？</li>
<li>以太坊接近历史高点：3 只股票在国债中堆积 ETH</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUdNUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUdNUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 IGM Biosciences 吗？</h2>
<p>在你考虑 IGM Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 IGM Biosciences 并不在名单上。</p>
<p>虽然 IGM Biosciences 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IGMS

<p>Wall Street Zen 将 IGM Biosciences (NASDAQ:IGMS) 的评级上调至 “持有”。该股票开盘价为 1.27 美元，52 周范围为 0.92 美元至 22.50 美元。IGM 报告每股收益为 1.58 美元，超出预期。该公司的市值为 7657 万美元，股本回报率为负 93.35%。最近，几家对冲基金增加了对 IGM 的持股。IGM 开发用于癌症和自身免疫疾病的 IgM 抗体，包括 Aplitabart 和 imvotamab</p>

<p>IGM Biosciences (NASDAQ:IGMS - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a &#34;hold&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>IGM Biosciences（纳斯达克代码：IGMS - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的股票研究人员上调至 “持有” 评级。</p>
</div><p>Get <strong>IGM Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>IGM Biosciences</strong> 的提醒：</p>
</div><h2>IGM Biosciences Price Performance</h2>
<div class="lb-trans"><h2>IGM Biosciences 价格表现</h2>
</div><p>Shares of IGMS stock opened at $1.27 on Friday. The stock has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $1.28. IGM Biosciences has a fifty-two week low of $0.92 and a fifty-two week high of $22.50. The stock has a market capitalization of $76.57 million, a P/E ratio of -1.41 and a beta of 0.60.</p>
<div class="lb-trans"><p>IGMS 股票在周五开盘价为 $1.27。该股票的 50 日简单移动平均线为 $1.27，200 日简单移动平均线为 $1.28。IGM Biosciences 的 52 周低点为 $0.92，52 周高点为 $22.50。该股票的市值为 7657 万美元，市盈率为 -1.41，贝塔值为 0.60。</p>
</div><p>IGM Biosciences (NASDAQ:IGMS - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $1.88. IGM Biosciences had a negative return on equity of 93.35% and a negative net margin of 36.81%. The business had revenue of $143.62 million during the quarter, compared to analysts' expectations of $3.20 million. On average, sell-side analysts anticipate that IGM Biosciences will post -3.35 earnings per share for the current year.</p>
<div class="lb-trans"><p>IGM Biosciences（纳斯达克代码：IGMS - 获取免费报告）最近在 7 月 31 日（星期四）公布了其财报。公司报告本季度每股收益为 $1.58，超出市场普遍预期的 ($0.30) 1.88 美元。IGM Biosciences 的股本回报率为 -93.35%，净利润率为 -36.81%。该公司在本季度的收入为 1.4362 亿美元，而分析师的预期为 320 万美元。平均而言，卖方分析师预计 IGM Biosciences 本年度每股收益为 -3.35。</p>
</div><h2>Institutional Investors Weigh In On IGM Biosciences</h2>
<div class="lb-trans"><h2>机构投资者对 IGM Biosciences 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of IGMS. XTX Topco Ltd acquired a new position in shares of IGM Biosciences in the 2nd quarter valued at $30,000. Invesco Ltd. acquired a new position in shares of IGM Biosciences in the 1st quarter valued at $42,000. Marshall Wace LLP acquired a new position in shares of IGM Biosciences in the 2nd quarter valued at $50,000. Nuveen LLC acquired a new position in shares of IGM Biosciences in the 1st quarter valued at $52,000. Finally, Deutsche Bank AG boosted its position in shares of IGM Biosciences by 316.6% in the 1st quarter. Deutsche Bank AG now owns 46,773 shares of the company's stock valued at $54,000 after purchasing an additional 35,546 shares during the period. 42.79% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 IGMS 的持仓。XTX Topco Ltd 在第二季度以 30,000 美元的估值新建了对 IGM Biosciences 的持仓。Invesco Ltd. 在第一季度以 42,000 美元的估值新建了对 IGM Biosciences 的持仓。Marshall Wace LLP 在第二季度以 50,000 美元的估值新建了对 IGM Biosciences 的持仓。Nuveen LLC 在第一季度以 52,000 美元的估值新建了对 IGM Biosciences 的持仓。最后，德意志银行在第一季度将其在 IGM Biosciences 的持仓增加了 316.6%。德意志银行目前拥有 46,773 股该公司的股票，估值为 54,000 美元，此前在此期间又购买了 35,546 股。42.79% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>IGM Biosciences Company Profile</h2>
<div class="lb-trans"><h2>IGM Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.</p>
<div class="lb-trans"><p>IGM Biosciences, Inc. 是一家临床阶段的生物技术公司，开发用于治疗癌症以及自身免疫和炎症性疾病的免疫球蛋白 M（IgM）抗体。它开发了 Aplitabart，一种用于治疗结直肠癌的死亡受体 5 激动剂 IgM 抗体；imvotamab，一种 CD20 x CD3 双特异性 IgM 抗体，用于治疗肌炎，以及用于治疗系统性红斑狼疮和类风湿关节炎，目前处于 I 期临床试验阶段；以及 IGM-2644，一种双特异性 T 细胞结合 IgM 抗体，靶向 CD38 和 CD3 蛋白，用于治疗自身免疫疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than IGM Biosciences</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>3 Restaurant Stocks That Will Outperform in Q3 and Q4</li>
<li>How to trade penny stocks: A step-by-step guide</li>
<li>The Midstream Energy Play That Keeps Powering Higher</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Ethereum Near All-Time High: 3 Stocks Stacking ETH in Treasuries</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 IGM Biosciences</li>
<li>如何在衰退中持有这些分红之王</li>
<li>3 只餐饮股票将在第三季度和第四季度表现优于大盘</li>
<li>如何交易便士股票：逐步指南</li>
<li>持续上涨的中游能源投资</li>
<li>便士股票适合你的投资组合吗？</li>
<li>以太坊接近历史高点：3 只股票在国债中堆积 ETH</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUdNUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=IGMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in IGM Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 IGM Biosciences 吗？</h2>
</div><p>Before you consider IGM Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 IGM Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IGM Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 IGM Biosciences 并不在名单上。</p>
</div><p>While IGM Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 IGM Biosciences 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

华尔街禅将 IGM Biosciences（NASDAQ:IGMS）的评级上调为持有